Form 4: Axsome Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Herriot Tabuteau, Chief Executive Officer, a Director and 10% owner of Axsome Therapeutics, Inc., sold 49,664 shares of common stock on August 5, 2026.
Summary
- Option exercise/conversion: acquired 45,004 Common Stock at $4.95 ($222,770) on August 5, 2026; holds 52,233 after (Direct).
- Open-market sale: disposed of 45,004 Common Stock at $212.01 ($9,541,298) on August 5, 2026; holds 7,229 after (Direct).
- Option exercise/conversion: acquired 4,660 Common Stock at $4.95 ($23,067) on August 6, 2026; holds 11,889 after (Direct).
- Open-market sale: disposed of 4,660 Common Stock at $213.95 ($997,007) on August 6, 2026; holds 7,229 after (Direct).
- Option exercise/conversion: disposed of 45,004 Stock Option (Right to Buy) on August 5, 2026; holds 4,660 after (Direct).
- Option exercise/conversion: disposed of 4,660 Stock Option (Right to Buy) on August 6, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $10,538,305 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Herriot Tabuteau — Director, Officer (Chief Executive Officer), 10% owner
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-05 | Option exercise/conversion | Common Stock | 45,004 | $5 | $222.8K | 52,233 |
| 2026-08-05 | Open-market sale | Common Stock | 45,004 | $212 | $9.5M | 7,229 |
| 2026-08-06 | Option exercise/conversion | Common Stock | 4,660 | $5 | $23.1K | 11,889 |
| 2026-08-06 | Open-market sale | Common Stock | 4,660 | $214 | $997.0K | 7,229 |
| 2026-08-05 | Option exercise/conversion | Stock Option (Right to Buy) | 45,004 | — | — | 4,660 |
| 2026-08-06 | Option exercise/conversion | Stock Option (Right to Buy) | 4,660 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-05 | Option exercise/conversion (45,004 shares) |
| 2026-08-05 | Open-market sale (45,004 shares) |
| 2026-08-06 | Option exercise/conversion (4,660 shares) |
| 2026-08-06 | Open-market sale (4,660 shares) |
| 2026-08-05 | Option exercise/conversion (45,004 shares) |
| 2026-08-06 | Option exercise/conversion (4,660 shares) |
Keywords
insider transaction, Form 4, AXSM, Axsome Therapeutics, Inc., bearish, Herriot Tabuteau
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.